RaySearch Laboratories AB (publ) (FRA:27R)
Germany · Delayed Price · Currency is EUR | Market Cap | 580.32M -20.2% |
| Revenue (ttm) | 114.69M +1.4% |
| Net Income | 19.24M +10.4% |
| EPS | 0.56 +10.7% |
| Shares Out | n/a |
| PE Ratio | 31.14 |
| Forward PE | 26.01 |
| Dividend | 0.37 (2.12%) |
| Ex-Dividend Date | May 8, 2026 |
| Volume | 640 |
| Open | 17.42 |
| Previous Close | 16.72 |
| Day's Range | 17.42 - 17.42 |
| 52-Week Range | 14.73 - 23.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About RaySearch Laboratories AB
RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer treatment worldwide. It offers RayStation, a treatment planning system for cancer centers; RayCare, an oncology information system for clinics; RayIntelligence, cloud-based oncology analytics system that cancer centers can use to gather, structure and analyze data; and RayCommand, a treatment control system designed to link the treatment machine and the treatment planning and oncology information systems. It also provides µ-RayStation* (Micro-... [Read more]
Financial Performance
In 2025, RaySearch Laboratories AB's revenue was 1.34 billion, an increase of 12.78% compared to the previous year's 1.19 billion. Earnings were 227.80 million, an increase of 11.94%.
Financial numbers in SEK Financial StatementsNews
RaySearch Laboratories AB Earnings Call Transcript: Q2 2026
Q2 2026 saw an 11% drop in net sales due to U.S. deal delays, but order intake rose 23% and recurring revenue provided stability. Management expects to recover postponed orders in Q3 and maintains a strong outlook for H2, aiming for a 25% EBIT margin for 2026.
RaySearch Laboratories AB Quarterly report: Q2 2026
RaySearch Laboratories AB has published its Q2 2026 quarterly earnings report on August 13, 2026.
RaySearch Laboratories AB Slides: Q2 2026
RaySearch Laboratories AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
RaySearch Laboratories AB Earnings Call Transcript: Q1 2026
Q1 2026 saw a 20% sales decline due to currency and timing of large deals, but profitability stayed strong with a 23% margin. Recurring revenue and order backlog remain robust, and momentum in RayCare and proton therapy segments supports a positive outlook.
RaySearch Laboratories AB Quarterly report: Q1 2026
RaySearch Laboratories AB has published its Q1 2026 quarterly earnings report on April 29, 2026.
RaySearch Laboratories AB Slides: Q1 2026
RaySearch Laboratories AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
RaySearch Laboratories AB Earnings Call Transcript: Q4 2025
Record net sales and profitability were achieved in 2025, driven by strong license and recurring revenues, major clinical milestones, and robust global demand. The company is confident in reaching a 25% EBIT margin in 2026 and has raised its dividend proposal, with new financial targets to be set during the year.
RaySearch Laboratories AB Quarterly report: Q4 2025
RaySearch Laboratories AB has published its Q4 2025 quarterly earnings report on February 12, 2026.
RaySearch Laboratories AB Slides: Q4 2025
RaySearch Laboratories AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 12, 2026.
RaySearch Laboratories AB Annual report: Q4 2025
RaySearch Laboratories AB has published its Q4 2025 annual report on February 12, 2026.
RaySearch Laboratories AB Earnings Call Transcript: Q3 2025
Record Q3 net sales and EBIT margin driven by strong license and support revenue growth, major customer wins, and robust demand for oncology software. Order intake rose 17%, with Pinnacle system replacements accelerating and RayCare interest intensifying.
RaySearch Laboratories AB Quarterly report: Q3 2025
RaySearch Laboratories AB has published its Q3 2025 quarterly earnings report on November 7, 2025.
RaySearch Laboratories AB Slides: Q3 2025
RaySearch Laboratories AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 7, 2025.
RaySearch Laboratories AB Earnings Call Transcript: Q2 2025
Q2 2025 saw a 4% sales decline due to delayed orders and tough year-over-year comparisons, but strong July order intake and a robust backlog support continued growth expectations. Operating margin was 12% (17% adjusted), and management maintains a 25% margin target by 2026.
RaySearch Laboratories AB Quarterly report: Q2 2025
RaySearch Laboratories AB has published its Q2 2025 quarterly earnings report on August 8, 2025.
RaySearch Laboratories: Interim report April - June 2025
STOCKHOLM , Aug. 8, 2025 /PRNewswire/ -- SECOND QUARTER (APRIL - JUNE 2025) Order intake amounted to SEK 241.2 M (290.3) Net sales amounted to SEK 304.9 (318.9) Operating profit amounted to SEK 36.4 M...
Invitation to presentation of RaySearch's interim report for the second quarter of 2025
STOCKHOLM , July 18, 2025 /PRNewswire/ -- Analysts, investors, and the media are invited to a presentation of RaySearch's interim report for the second quarter of 2025, on August 8, 2025, at 10.00 am ...
RaySearch Laboratories AB Earnings Call Transcript: Q1 2025
Record Q1 sales and order intake drove a 29% revenue increase and a 23% operating margin, with strong license and support growth. Major orders, new product launches, and robust cash flow support a positive outlook and margin target of 25% by 2026.
RaySearch Laboratories AB Quarterly report: Q1 2025
RaySearch Laboratories AB has published its Q1 2025 quarterly earnings report on May 9, 2025.
Interim report January 1 - March 31, 2025: RaySearch Laboratories
STOCKHOLM , May 9, 2025 /PRNewswire/ -- FIRST QUARTER (JANUARY - MARCH 2025) Order intake amounted to SEK 409.6 M (238.5) Net sales amounted to SEK 331.7 M (257.2) Operating profit amounted to SEK 74...
RaySearch Laboratories and Vision RT present innovations in surface guided treatment planning at ESTRO
STOCKHOLM , May 3, 2025 /PRNewswire/ -- At this week's ESTRO conference in Vienna, RaySearch Laboratories AB (publ) and Vision RT proudly announces the next step in their collaboration: the full integ...
Invitation to presentation of RaySearch's interim report for the first quarter of 2025
STOCKHOLM , April 25, 2025 /PRNewswire/ -- Analysts, investors, and the media are invited to a presentation of RaySearch's interim report for the first quarter of 2025, on May 9, 2025, at 10.00 am CES...
Completed placing of shares in RaySearch Laboratories AB (publ)
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION ...
Contemplated placement of existing shares in RaySearch Laboratories AB
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION ...
RaySearch Laboratories AB Earnings Call Transcript: Q4 2024
Record sales and operating profit were achieved in 2024, with strong growth in license and support revenues, a robust cash position, and a proposed dividend increase. The outlook for 2025 remains positive, with continued investment and a raised operating margin target.